MARATTO

article · Beni-Suef University Journal of Basic and Applied Sciences

Insilco study on the toxicity of anti-cancer compounds tested against MOLT-4 and p388 cell lines using GA-MLR technique

201617 citationsOpen accessAhmadu Bello University

Abstract

The research entails the development of two models that can be used to predict the toxicity of compounds suspected of having anti-leukemia activity, the two models, one for MOLT-4 and the other for P388 cell lines, were developed by carefully selecting 5 descriptors in each case from a pool of 4900 molecular descriptors using GA-MLR method. The ability of the models to predict chemicals that were not used in the preparation set was evaluated by validating the models internally [Q2CV MOLT-4 = 0.644 and Q2CV (P388) = 0.641] and externally [R2pred (P388) = 0.662 and R2pred (MOLT-4) = 0.679], other criteria such as r2m, R2p, k and k′ were also determined and were found to support R2pred results of the models. The effects of every descriptor in the model were dictated by calculating their individual mean effect to (pLC50) the toxicities of the compounds. SpMax7_Bhm (1.697) and RDF145u (−4.300) influenced the models the most, while in MOLT-4 the descriptors with the least effect was n-isopropyl (0.0343) and for P388 is 1.162. The models were further validated by subjecting them to y-randomization which finally confirmed the robustness of the models developed.

Research topics

  • Computational Drug Discovery Methods
  • Analytical Methods in Pharmaceuticals
  • Pesticide Residue Analysis and Safety

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1016/j.bjbas.2016.11.003

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.